APPEN
7.3.2019 17:02:08 CET | Business Wire | Press release
Appen Limited today announced the achievement of ISO/IEC 27001:2013 accreditation for its facility in Cavite, Philippines to meet the rapidly growing demand for human-annotated datasets used by companies worldwide to train machine learning and artificial intelligence (AI) applications.
The facility was established to ensure commercial confidentiality and better support privacy management. Globally recognized, the ISO/IEC 27001:2013 standard defines the requirements for an Information Security Management System (ISMS), and a process-based approach for establishing, implementing, operating, monitoring, maintaining and improving the ISMS.
ISO/IEC 27001:2013 accreditation underpins Appen’s ability to work on datasets for clients that contain personally identifiable information – data that could potentially identify a specific individual – as well as other sensitive material, such as data related to new product development.
“Appen’s facility in the Philippines gives clients enhanced options to scale their AI programs with the assurance that their sensitive data and projects will remain secure,” said Mark Brayan, Appen’s chief executive officer. “It’s the perfect complement to our high-security facility in the U.K., and is an important part of our suite of secure at-home and in-facility solutions.”
Appen works with the world’s leading technology companies, as well as firms across all industries to provide high-quality data for their machine learning programs. Appen’s suite of secure solutions includes secure facilities as well as secure remote worker options designed to scale customers’ machine learning programs while maintaining data privacy. Use case examples range from voice recognition in smart speakers to geospatial analysis in self-driving cars, to intelligent search and online advertising results.
Industry analysts estimate the data collection and annotation market will be worth up to $19 billion – approximately 10% of the overall AI market – by 2025. The explosive growth is attributed to the need for high volumes of annotated data that are required to improve AI algorithm accuracy. Today, approximately one-third of AI applications require frequent or monthly data updates, and one-quarter of those need weekly updates, according to McKinsey Global Institute.
Datasets created by Appen include image, text, audio, video and relevance data, as well as speech and natural language data from over 130 countries and more than 180 languages and dialects.
The announcement today follows Appen’s recent reporting of record results of AU$364.3 million in 2018, representing 119% growth year-over-year.
During the company shareholder call last week, Brayan outlined Appen’s 2019 growth initiatives that include increasing technology development to improve the productivity of its global crowd of over 1 million skilled contractors who develop the AI training datasets in conjunction with Appen’s Client Services team. In addition to expanding Appen’s secure solutions, the company also plans to increase its full-time staff and investments in China, the largest AI market outside of the U.S.
Founded in 1996, Appen has office locations worldwide including Seattle, San Francisco, Detroit, and Beijing in addition to the Philippines, U.K. and its headquarters in Sydney.
About Appen
Appen is a global leader in the development of high-quality, human-annotated datasets for machine learning and artificial intelligence. Appen brings over 20 years of experience capturing and enriching a wide variety of data types including speech, text, image, and video. With deep expertise in more than 180 languages and access to a global crowd of over 1 million skilled contractors, Appen partners with technology, automotive and e-commerce companies — as well as governments worldwide — to help them develop, enhance and use products that rely on natural languages and machine learning.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190307005137/en/
Contact:
Jodie Ruby VP of Marketing jruby@appen.com 425-442-8014
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
